Optimal Therapy for Early-Stage Hodgkin’s Lymphoma

Risk Adapting, Response Adapting, and Role of Radiotherapy

Andrea Riccardo Filippi, Mario Levis, Rahul Parikh, Bradford Hoppe

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of Review: The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin’s lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. Recent Findings: In low-risk patients, RT could be omitted but, at the price of a lower progression-free survival, and its role is still debated. Ongoing trials are combining new agents with chemotherapy alone or response-adapted combined modality therapy, and results are awaited. Modern RT incorporates lower doses and smaller fields, together with the implementation of sophisticated delivery techniques aimed to reducing the dose to critical structures such as the heart. Summary: The role of RT for early-stage HL is still under debate, and new combinations are emerging; an individualized approach should be recommended, considering all RT technical opportunities to minimize toxicity while maintaining efficacy.

Original languageEnglish (US)
Article number34
JournalCurrent oncology reports
Volume19
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Hodgkin Disease
Radiotherapy
Therapeutics
Combined Modality Therapy
Disease-Free Survival
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Keywords

  • Early stage
  • Hodgkin’s lymphoma
  • Proton therapy
  • Radiotherapy

Cite this

@article{ec6da626897b41b3a85682d7b16c1d76,
title = "Optimal Therapy for Early-Stage Hodgkin’s Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy",
abstract = "Purpose of Review: The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin’s lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. Recent Findings: In low-risk patients, RT could be omitted but, at the price of a lower progression-free survival, and its role is still debated. Ongoing trials are combining new agents with chemotherapy alone or response-adapted combined modality therapy, and results are awaited. Modern RT incorporates lower doses and smaller fields, together with the implementation of sophisticated delivery techniques aimed to reducing the dose to critical structures such as the heart. Summary: The role of RT for early-stage HL is still under debate, and new combinations are emerging; an individualized approach should be recommended, considering all RT technical opportunities to minimize toxicity while maintaining efficacy.",
keywords = "Early stage, Hodgkin’s lymphoma, Proton therapy, Radiotherapy",
author = "Filippi, {Andrea Riccardo} and Mario Levis and Rahul Parikh and Bradford Hoppe",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s11912-017-0592-7",
language = "English (US)",
volume = "19",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "5",

}

Optimal Therapy for Early-Stage Hodgkin’s Lymphoma : Risk Adapting, Response Adapting, and Role of Radiotherapy. / Filippi, Andrea Riccardo; Levis, Mario; Parikh, Rahul; Hoppe, Bradford.

In: Current oncology reports, Vol. 19, No. 5, 34, 01.05.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Optimal Therapy for Early-Stage Hodgkin’s Lymphoma

T2 - Risk Adapting, Response Adapting, and Role of Radiotherapy

AU - Filippi, Andrea Riccardo

AU - Levis, Mario

AU - Parikh, Rahul

AU - Hoppe, Bradford

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Purpose of Review: The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin’s lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. Recent Findings: In low-risk patients, RT could be omitted but, at the price of a lower progression-free survival, and its role is still debated. Ongoing trials are combining new agents with chemotherapy alone or response-adapted combined modality therapy, and results are awaited. Modern RT incorporates lower doses and smaller fields, together with the implementation of sophisticated delivery techniques aimed to reducing the dose to critical structures such as the heart. Summary: The role of RT for early-stage HL is still under debate, and new combinations are emerging; an individualized approach should be recommended, considering all RT technical opportunities to minimize toxicity while maintaining efficacy.

AB - Purpose of Review: The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin’s lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach. Recent Findings: In low-risk patients, RT could be omitted but, at the price of a lower progression-free survival, and its role is still debated. Ongoing trials are combining new agents with chemotherapy alone or response-adapted combined modality therapy, and results are awaited. Modern RT incorporates lower doses and smaller fields, together with the implementation of sophisticated delivery techniques aimed to reducing the dose to critical structures such as the heart. Summary: The role of RT for early-stage HL is still under debate, and new combinations are emerging; an individualized approach should be recommended, considering all RT technical opportunities to minimize toxicity while maintaining efficacy.

KW - Early stage

KW - Hodgkin’s lymphoma

KW - Proton therapy

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85016728096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016728096&partnerID=8YFLogxK

U2 - 10.1007/s11912-017-0592-7

DO - 10.1007/s11912-017-0592-7

M3 - Review article

VL - 19

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

M1 - 34

ER -